Ovarian Cancer (Clinical Trials)

Funding Received To Assist in Developing Cancer Vaccine

Published in Cancer Weekly, March 24th, 1997

AltaRex Corp., Edmonton, Alberta, Canada, announced the approval of funding from the Alberta Heritage Foundation For Medical Research (AHFMR) to assist in carrying out the Canadian Phase II/III clinical trial of Ovarex therapeutic vaccine for the treatment of advanced ovarian cancer.

For this trial, more than 200 patients have been enrolled in 15 participating trial centers across Canada. A similar trial of the same magnitude has been taking place in Europe.

"The AltaRex Ovarex program is another excellent example of basic research moving from the lab to the marketplace," commented Dr. Matt Spence, AHFMR. Dr. Antoine (Tony) Noujaim, AltaRex, said,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry